<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Aditi Talwar on Medium]]></title>
        <description><![CDATA[Stories by Aditi Talwar on Medium]]></description>
        <link>https://medium.com/@adititalwar777?source=rss-06ff44c755c2------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Stories by Aditi Talwar on Medium</title>
            <link>https://medium.com/@adititalwar777?source=rss-06ff44c755c2------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 07:08:08 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@adititalwar777/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[How I Built a Phage Genome Database Inspired by PhageScope]]></title>
            <link>https://medium.com/@adititalwar777/how-i-built-a-phage-genome-database-inspired-by-phagescope-a990a1057b93?source=rss-06ff44c755c2------2</link>
            <guid isPermaLink="false">https://medium.com/p/a990a1057b93</guid>
            <category><![CDATA[phage-data-base]]></category>
            <category><![CDATA[phage-therapy]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[bacteriophages]]></category>
            <category><![CDATA[website]]></category>
            <dc:creator><![CDATA[Aditi Talwar]]></dc:creator>
            <pubDate>Fri, 30 Oct 2026 04:37:17 GMT</pubDate>
            <atom:updated>2026-10-30T05:05:27.678Z</atom:updated>
            <content:encoded><![CDATA[<p>In my last article, I talked about one of the biggest challenges in phage therapy: finding the right phage for a specific bacterial infection. There are millions of phage sequences out there, but having all that information doesn’t help much if you can’t actually search through it, compare it, or understand what you’re looking at.</p><p>That got me thinking about what a database like that actually looks like behind the scenes. I wanted to see if I could build a smaller version myself.</p><p>That’s how I started working on PhageVault, a phage genome database prototype I built using Base44. It was inspired by PhageScope, an open-access phage database and analysis platform. I knew I wasn’t going to recreate everything PhageScope does. It has a huge amount of data and real bioinformatics tools behind it. My goal was more about understanding how the platform was put together and seeing how much of that structure I could recreate myself.</p><h3>Why Build a Phage Database?</h3><p>Phage therapy depends a lot on information. If researchers are looking at a phage as a possible treatment, they need to know things like what bacteria it infects, what its genome looks like, whether it is lytic or temperate, and whether there are genes that could cause safety concerns.</p><p>Having all of this information in one place can make the process much easier. Instead of looking through different sources every time, researchers can search a database, use filters, and compare different phages.</p><p>I also wanted this to be a challenge for myself. Instead of just coming up with a completely new website, I thought it would be more interesting to take something that already exists and try to figure out how it works.</p><p>I wanted to understand not just what each feature did, but why it was there.</p><h3>Choosing What to Replicate</h3><p>Choosing what to build actually took some time. I looked at a bunch of different phage-related websites, but a lot of them were mainly information pages, older databases, or individual research tools.</p><p>I wanted something I could actually interact with.</p><p>I was looking for searchable data, filters, genome information, analysis tools, and an interface that was easy to move around.</p><p>That’s what made PhageScope stand out to me.</p><p>PhageScope contains millions of phage sequences and organizes information about things like hosts, environments, genomes, proteins, and annotations. It also has tools that can make predictions about things such as host, lifestyle, and taxonomy.</p><p>What interested me most was that it wasn’t just a huge collection of data. The information was organized in a way that helped a researcher actually use it.</p><p>That’s what I wanted to try to recreate with PhageVault.</p><h3>Studying the Original</h3><p>Before I started building anything, I spent a lot of time just going through PhageScope.</p><p>I looked at the homepage, menus, database pages, genome annotation tools, workspace, and even smaller things like the footer. I took notes on the different sections, table columns, filters, and how the pages connected.</p><p>This ended up being more important than I expected.</p><p>Instead of opening Base44 and saying, “Make me a phage database,” I already had an idea of what I wanted because I had actually used the original platform.</p><p>One thing I noticed was that PhageScope seemed to be organized around questions a researcher might have.</p><p>What phages are available? What bacteria do they infect? Where were they found? What genes and proteins do they have? How are they related to other phages?</p><p>I wanted PhageVault to have some of that same logic behind it.</p><h3>What I Decided to Build</h3><p>After looking through PhageScope, I started breaking down what I actually wanted in my own version.</p><p>The first thing was a searchable phage database. I wanted users to be able to browse different phages and find information about them without having to go through every record manually.</p><p>I also made individual phage pages. Instead of having everything crammed into one giant table, each phage could have its own page with its information organized in one place. I added things like genome visualization and protein information to make the pages feel more like actual scientific records.</p><p>I also wanted to recreate the genome annotation section.</p><p>PhageScope allows researchers to submit sequences for actual computational analysis. My version doesn’t do that. I recreated the general workflow and interface, but the predictions in PhageVault are simulated.</p><p>I also added a workspace where analysis tasks can be displayed with information like the task name, analysis type, status, and creation time.</p><p>While building all of this, I started realizing that a scientific database isn’t just about storing information. It also needs to help someone move from finding information, to analyzing it, to comparing what they found.</p><h3>Writing the Build Prompt</h3><p>Once I had a better idea of what I wanted, I started turning all of my notes into instructions for Base44.</p><p>At first, I thought I could just give it one really detailed prompt and it would build everything.</p><p>That didn’t work as well as I expected.</p><p>I ended up breaking the project into smaller pieces. I started with the general design and things like the navigation, fonts, buttons, cards, and page layouts. Then I moved into the actual pages, including the homepage, phage lists, phage detail pages, annotation page, and workspace.</p><p>One thing I learned pretty quickly was that <strong>being specific matters a lot.</strong></p><p>If I asked for “a searchable phage table,” I would get something that technically worked, but it wasn’t really what I had in mind.</p><p>When I explained the exact columns I wanted, what the filters should do, what should happen when there were no results, and how the user should interact with the table, the result was much closer.</p><p>Eventually, I gave myself two rules:</p><p>Understand and recreate the important structure and functionality of PhageScope.</p><p>Make PhageVault my own project instead of trying to make an exact copy.</p><p>The second one became especially important later.</p><h3>The Biggest Problem: Data</h3><p>This was probably the hardest part.</p><p>PhageScope has more than 2.5 million phage sequences and over 130 million proteins. There was no realistic way for me to put that amount of biological data into a Base44 project.</p><p>So I had to think of another way.</p><p>I ended up creating a seeded data generator. Instead of storing millions of individual records, PhageVault generates sample records based on an ID using consistent rules. This means the same ID can produce the same information without me actually having to store millions of records.</p><p>Technically, this solved the problem.</p><p>But it also made something very important clear, the generated records are not real biological data. It is a prototype showing how a phage database could be organized and how someone could interact with it.</p><p>Building in Phases</p><p>I also learned that trying to build everything at once was not the best approach.</p><p>I started with the basic structure, like the navigation, footer, and page routes. Then I worked on the data system that would generate the sample records.</p><p>After that, I built the homepage and connected it to the data.</p><p>Once that was working, I moved onto the database pages and individual phage pages. Then I worked on the annotation page and workspace before adding comparison features and other parts of the site.</p><p>After each major step, I tested it before moving on.</p><p>There was definitely a lot of trial and error. Sometimes something would break and I had to figure out what I had changed or what was causing the problem.</p><p>But working in smaller phases made that much easier. If something stopped working, I usually had a pretty good idea of where to look.</p><h3>Where I Got Stuck</h3><p>One of the biggest mistakes I made was trying too hard to make PhageVault look exactly like PhageScope.</p><p>At first, I thought that was what I was supposed to do. But after a while, I realized that making an exact copy wasn’t really the point.</p><p>I don’t have access to PhageScope’s source code or backend, so I couldn’t just copy how everything worked.</p><p>Instead, I started asking myself:</p><p>Why did they design this feature this way? And how can I recreate the same idea?</p><p>That completely changed how I approached the project.</p><p>The amount of data was another major challenge. I needed to find a way to represent millions of records without actually storing millions of records. This was one of the areas where I used AI the most. I went through different ideas for generating and organizing the data before eventually settling on the seeded data system.</p><p>I also realized that I hadn’t studied every part of PhageScope equally. There were pages where I had taken a lot of notes and others where I hadn’t really looked closely enough.When I eventually got to those parts while building, I had to go back to the original site and figure them out.That taught me something pretty simple: doing enough research before you start building can save you a lot of time later.</p><h3>What I Learned</h3><p>The biggest thing I learned was that the quality of what I built depended a lot on how well I understood what I was trying to build.</p><p>When my instructions were vague, the results were usually vague too.</p><p>When I actually understood what I wanted a feature to do and explained it clearly, the result was much better.</p><p>I also learned how important consistency is when working with data. Even though the data in PhageVault is simulated, I still wanted it to make sense across the website. If one page said one thing and another page showed something completely different, the whole database would feel unreliable.</p><p>But probably the biggest lesson for me was realizing how different the interface of a scientific tool is from the science behind it.PhageVault recreates parts of the experience, but it doesn’t recreate that scientific pipeline.Understanding that gave me a much better appreciation for how much work actually goes into building a platform like PhageScope.</p><h3>How Someone Else Could Replicate This Project</h3><p>If someone wanted to try something similar, I would recommend using the original tool first before trying to build your own version.</p><p>Go through the pages. Open the menus. Try the filters. Pay attention to the small details.</p><p>Then break the project into smaller parts instead of giving an AI builder one massive request.</p><p>Build the navigation first. Then the data structure. Then one database page. Test it, fix it, and then move on.</p><p>If the original platform has more data than you can realistically reproduce, generated sample data can be useful for a prototype. But it needs to be clearly labeled as simulated.</p><p>AI was also really useful to me during this project. I used it for prompts, debugging, and working through technical problems.</p><p>But I also learned that AI works a lot better when you already understand what you’re trying to do.</p><p>It can help you build something, but you still have to know what you want it to build.</p><h3>Conclusion</h3><p>Building PhageVault changed the way I look at phage databases.</p><p>Before this project, I mostly saw PhageScope as a website with a huge amount of phage information. After trying to recreate parts of it, I realized that the website is really just the part you can see.</p><p>Behind it are systems for collecting sequences, analyzing genomes, predicting biological characteristics, organizing proteins, comparing phages, and making all of that information searchable.</p><p>This connects back to why I became interested in the project in the first place: phage therapy.</p><p>Finding a phage is only one part of the problem. Researchers also need to know what that phage infects, understand its genome, compare it with other phages, look for potential risks, and figure out which candidates are worth investigating further.</p><p>PhageVault doesn’t solve those problems. But building it helped me understand the kind of infrastructure that researchers need in order to work with such a large amount of phage information.</p><p>More than anything, this project taught me that recreating a scientific tool isn’t really about copying what you see on the screen. It’s about understanding why it was designed that way and what is happening behind it.</p><p>That is what made building PhageVault valuable to me.</p><p>PhageVault Link : <a href="https://phage-vault-core.base44.app/">https://phage-vault-core.base44.app/</a></p><p>PhageScope Link : <a href="https://phagescope.deepomics.org/">https://phagescope.deepomics.org/</a></p><h4>About the Author</h4><p>Hi, my name is Aditi! I am a high school student passionate about Science. I always had a passion for science since I was a little girl; learning about new emerging technology’s in science is one of my favourite things to research. You can reach out to me through my email adititalwar777@gmail.com and my <a href="https://www.linkedin.com/in/aditi-t-5bb69142a/">LinkedIn</a>!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a990a1057b93" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How could phage therapy potentially help address infections caused by multidrug-resistant bacteria…]]></title>
            <link>https://medium.com/@adititalwar777/how-could-phage-therapy-potentially-help-address-infections-caused-by-multidrug-resistant-bacteria-36488155c724?source=rss-06ff44c755c2------2</link>
            <guid isPermaLink="false">https://medium.com/p/36488155c724</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[phage-therapy]]></category>
            <category><![CDATA[multidrug-resistance]]></category>
            <category><![CDATA[antibiotic-resistance]]></category>
            <dc:creator><![CDATA[Aditi Talwar]]></dc:creator>
            <pubDate>Tue, 29 Sep 2026 01:40:30 GMT</pubDate>
            <atom:updated>2026-09-30T00:54:33.483Z</atom:updated>
            <content:encoded><![CDATA[<h3>How could phage therapy potentially help address infections caused by multidrug-resistant bacteria, and what challenges must scientists overcome before it can be widely used</h3><p>For generations, antibiotics have been one of the greatest breakthroughs in science and an extremely powerful tool for treating infections. But what happens when bacteria learn to evolve alongside antibiotics? As bacteria evolve, some bacteria have developed the ability to survive many antibiotics. When an infection becomes resistant to antibiotics, what do we do?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/679/1*OiMHe_nPUGms5xQS-GpYGw.jpeg" /></figure><p>As antibiotic resistance continues to affect millions, scientists have been working on finding alternative ways of targeting antibiotic-resistant infections. One approach has been in the public eye for a while, since 1917, and it is phage therapy. Phage therapy uses bacteriophages, also known as phages, which are viruses that infect bacteria. In fact, phages are found everywhere: in water, soil, and even sewage. Instead of using a drug to stop the production or growth of bacteria, phages recognize certain bacteria, infect them, reproduce inside the bacteria, and, in the case of lytic phages, destroy the bacterial cell.</p><p>Advancements made in microbiology, genetics, and biotechnology have allowed researchers to reinvent what phage therapy can look like in the near future. Scientists are now studying how phages recognize bacteria, why some phages can infect certain strains but not all strains, and whether phages can be combined with antibiotics to improve their use. However, there are many complications within phage therapy, including bacterial resistance, manufacturing, treatment speed, and the need for stronger clinical evidence regarding phage therapy.</p><p>The question comes down to whether scientists can develop phage-based treatments that are safe, accurate, fast enough, and practical enough to be widely used.</p><h3>The Problem: MDR Bacteria</h3><p>To understand the relationship between phage therapy and multidrug-resistant bacteria, it is essential to understand antibiotic resistance. Antibiotics are medicines designed to kill bacteria or prevent bacteria from growing. Nonetheless, different antibiotics have different ways of killing bacteria or slowing their growth. Some antibiotics interfere with the cell wall, while others interfere with protein production, DNA replication, or other processes necessary for bacterial survival.</p><p>Nevertheless, bacteria are not passive targets; they can evolve. When an antibiotic is used against a bacterial population, susceptible bacteria may be killed; however, bacteria with resistance survive. The bacteria that survive are able to multiply, allowing the trait of resistance to become more common. Bacteria can also acquire resistance genes from other bacteria, allowing the resistance trait to spread.</p><p>Resistance to one antibiotic is an issue, but resistance to many antibiotics is a serious issue. Multidrug-resistant bacteria can withstand multiple antibiotics, leaving healthcare professionals with fewer treatment possibilities.</p><p>The issue is not that antibiotics will stop working altogether. Rather, resistance can make infections difficult to manage, especially when bacteria are resistant to several classes of antibiotics. Bacteria such as <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter baumannii</em>, and certain strains of <em>E. coli</em> can cause difficult-to-treat infections.</p><h3>What Are Bacteriophages?</h3><p>Bacteriophages are viruses that target bacteria. Unlike viruses that target human cells, bacteriophages specifically target bacterial hosts. Phages can be found throughout the natural environment, including soil, water, and sewage. Their role in the ecosystem is to infect and regulate bacterial populations.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/474/1*rFUnyXGbiU5GGjd1OVKF7g.jpeg" /></figure><p>A typical phage contains genetic material enclosed within a protein structure. Many phages also have tail structures that help them recognize and attach to bacterial cells. This recognition is crucial, as phages are often specific about which bacteria they can infect.</p><p>The specificity is one of the most important differences between phages and many antibiotics. Antibiotics can affect a range of bacteria depending on the drug, while a particular phage will only be able to infect certain strains.</p><h3>How Does Phage Therapy Work?</h3><p>The process begins when the phage encounters a suitable bacterial cell. The phage will recognize a receptor on the bacterial surface and attach to it. It will then introduce its genetic material into the infected cell.</p><p>Phage therapy uses bacteriophages to target bacterial infections. For therapeutic applications, researchers are particularly interested in lytic phages. Lytic phages infect a susceptible bacterium and use the bacterial cell to produce more phages. Eventually, the bacterial cell breaks apart, releasing newly produced phages to infect other bacteria.</p><p>The ability to reproduce in susceptible bacterial populations is extremely scientifically interesting. However, it does not mean that phages can automatically eliminate any bacterial infection. The phage can only eliminate the bacteria that it recognizes.</p><h3>The Host-Range Problem</h3><p>One of the biggest challenges in phage therapy is called host range. Host range refers to the types of bacteria that a particular phage can infect.</p><p>For instance, a phage might infect one strain of <em>Pseudomonas aeruginosa</em> but fail to infect another strain. This demonstrates how bacteria belonging to the same species can have differences on their surfaces that prevent a particular phage from recognizing them.</p><p>This creates a major issue: a doctor cannot select just any phage and expect it to work. The patient’s bacterial infection first needs to be identified, and researchers may then need to determine which available phage can infect that specific strain.</p><p>This process can make phage therapy more personalized than a conventional antibiotic treatment. However, this can ultimately lead to treatment being slower and more complicated.</p><p>Recent research from McMaster University provides an example of why host range matters. Researchers studied <em>Pseudomonas aeruginosa</em>, a bacterium that can cause serious infections and can be multidrug-resistant. They examined the relationship between phages and structures called type IV pili on the surface of <em>Pseudomonas</em>.</p><p>Pili are hair-like structures that can serve functions for bacteria, like movement and attachment. They can also act as receptors that certain phages use to attach to bacteria. The McMaster researchers analyzed genetic data from more than 1,300 <em>P. aeruginosa</em> strains and identified 53 distinct pilus variants.</p><p>The study found a relationship between bacterial pili and the structure of phage tail fibres. Broader-acting phages had more structural diversity in portions of their tail fibres involved in interacting with bacterial pili.</p><p>This research is important because it addresses one of the central problems of phage therapy: finding a phage that can infect the bacteria responsible for a patient’s infection.</p><h3>Bacteria Can Fight Back</h3><p>Although phages can kill bacteria, bacteria can evolve resistance to phages. Evolution does not stop because the threat is a virus instead of an antibiotic. For example, if a phage requires a particular receptor on the bacterial surface to attach, a bacterium could change or stop producing that receptor, causing phage resistance.</p><p>However, an interesting aspect of phage resistance is that becoming resistant to a phage can have consequences for the bacterium.</p><p>The McMaster research group studied how <em>Pseudomonas aeruginosa</em> can evade phages by reducing the production or function of pili. Although this can help the bacterium avoid certain phages, pili are important for bacterial movement, attachment, and disease-related functions. Researchers are looking into the possibility of using phage pressure to push bacteria toward less harmful characteristics using <strong>phage steering</strong>.</p><p>This brings up an interesting idea: instead of only trying to kill bacteria, researchers could potentially use phages to put pressure on bacteria and influence the way they evolve. If bacteria change their pili to become resistant to a phage, that change could also affect other characteristics of the bacteria. In some cases, the bacteria may become less capable of movement, attachment, or other functions that can contribute to infection.</p><p>This does not mean that phage steering will automatically make bacteria harmless. It is still an area that requires more research. However, it shows that phage therapy could potentially work in a different way from traditional antibiotics. Scientists may not only be trying to kill the bacteria; they could also be studying how bacterial evolution can be used against them.</p><h3>Phage Cocktails and Combination Treatments</h3><p>As a result of phages being unable to infect every strain of a bacterial species, researchers can combine multiple phages to create a phage cocktail.</p><p>For example, imagine Phage X can infect bacterial strains one and two, while Phage Y can infect strains three and four. Combining both phages can potentially result in broader coverage rather than using one phage alone.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/464/1*z-6vkOzmOwL9qQJYYdLC0Q.jpeg" /></figure><p>Phage cocktails also make it more difficult for bacteria to develop resistance, as they would need to develop resistance to multiple phages. However, phage cocktails are not a guaranteed solution. Bacteria can still develop resistance; it may just be more difficult to develop resistance to multiple phages compared to only one phage.</p><p>Another strategy is combining phages with antibiotics. The idea is to use two different antimicrobial approaches together. Phages can attack bacteria through mechanisms that differ from those of antibiotics, and researchers are currently investigating whether certain phage-antibiotic combinations can produce synergistic effects.</p><p>This is particularly interesting for MDR infections because even if an antibiotic is not able to eliminate an infection by itself, it may still have a useful role when combined with another treatment. However, the effectiveness of combinations depends on the particular phage, bacterium, and antibiotic.</p><h3>Why Isn’t Phage Therapy Used Everywhere?</h3><p>If phages can kill bacteria, an obvious question is: why aren’t they already replacing antibiotics?</p><p>The answer is that killing bacteria in a lab is different from treating an infection in a human being.</p><p>Firstly, researchers need to identify a suitable phage. A phage may work extremely well against one bacterial strain but fail against another. Secondly, bacteria can also develop phage resistance. Third, the human immune system can interact with phages and clear them from the body. Researchers will also have to determine how phages should be delivered, how much should be given to patients, how often treatment should be given, and if the phages can reach the location of the infection.</p><p>Manufacturing can also be a challenge. Phages need to be produced and purified under controlled conditions. Since phages are biological agents that are often selected or customized for specific bacterial strains, the process is more complicated than producing a conventional drug.</p><p>This becomes an even bigger problem when treatment needs to be personalized. If doctors need to identify the bacteria, find a matching phage, create a cocktail, and then produce and purify it, the process could take valuable time. A severe infection may not give doctors enough time to wait for a completely personalized treatment.</p><p>This means that for phage therapy to become more practical, scientists would need faster ways to identify bacteria and match them with phages. Larger collections of already-characterized phages could help researchers find a suitable match more quickly instead of starting from scratch each time.</p><h3>What Would Need to Change for Phage Therapy to Become Practical?</h3><p>For phage therapy to become more widely used, scientists would need to make the process faster and more reliable. Researchers would need larger collections of well-characterized phages, faster ways to identify the bacteria causing an infection, and better ways to match a patient’s bacteria with the right phage.</p><p>Manufacturing would also need to become more efficient. If every patient requires a completely different phage or phage cocktail, producing and purifying those treatments could become difficult on a large scale.</p><p>Overall, phage therapy may need to become a system that can quickly identify the bacteria, find the right phage, produce the treatment, and adapt if the bacteria develop resistance.</p><h3>What Does the Clinical Evidence Show?</h3><p>There are examples of patients with difficult MDR infections who have received experimental phage therapy and improved.</p><p>One well-known case involves Tom Patterson, a patient with a severe <em>Acinetobacter baumannii</em> infection. Researchers searched through phage collections and identified phages capable of attacking his bacterial isolate. Tom received a phage cocktail and improved significantly. The case helped bring attention to phage therapy in the United States and globally.</p><p>Cases like this are extremely important because they demonstrate that phage therapy can be used in patients. However, a single case cannot establish that phage therapy will work for every patient and infection.</p><p>Therefore, phage therapy should not be described as a proven universal replacement for antibiotics. Instead, it is better understood as a developing treatment strategy.</p><h3>The Future of Phage Therapy</h3><p>The future of phage therapy may involve several approaches working together.</p><p>Scientists could develop larger libraries of characterized phages, allowing them to find a suitable phage more efficiently when a patient has an MDR infection. Researchers could also use genetic information to predict which phages will infect particular bacterial strains. The discovery at McMaster University of structural characteristics associated with broader phage activity could potentially contribute to this process by helping researchers identify phages capable of recognizing more diverse bacterial receptors.</p><p>Researchers could also continue investigating phage steering and whether bacterial evolution can be used as part of treatment. Instead of only asking whether a phage can kill a bacterium, scientists could ask what happens to the bacterium when it evolves resistance to that phage.</p><p>These approaches could make phage therapy more practical and precise. However, they also require continued research in safety, manufacturing, bacterial evolution, treatment speed, and clinical effectiveness.</p><p>The biggest challenge may not be discovering a “super-phage” that can kill every type of bacteria. Instead, the challenge may be building the infrastructure needed to quickly identify the bacteria, find the right phage, manufacture and purify it, treat the patient, and adapt the treatment if the bacteria evolve resistance.</p><h3>Conclusion</h3><p>Multidrug-resistant bacteria are creating a growing challenge because some infections can become difficult to treat with conventional antibiotics. Phage therapy offers a different biological approach by using bacteriophages that specifically infect bacteria.</p><p>However, phage therapy is not a simple replacement for antibiotics. A phage may be able to kill one bacterial strain while being ineffective against another. Bacteria can develop resistance to phages, while researchers must overcome challenges involving delivery, immune responses, manufacturing, treatment speed, and clinical evidence.</p><p>The future of phage therapy may depend less on discovering one “super-phage” and more on building a system that can quickly match, manufacture, deliver, and adapt phage treatments to individual infections. If scientists can make this process fast enough for patients who need immediate treatment, phage therapy could become a more practical tool for treating some multidrug-resistant infections. This would allow phage therapy to develop from an experimental treatment into another possible tool for managing infections that are becoming increasingly difficult to treat.</p><p><strong>Works cited</strong></p><p>Alzahrani, Ahmed J. “Bacteriophage Therapy against Multidrug Resistant Bacterial Infections Demonstrates Clinical Advances and Engineering Innovations between 2020–2026.” <em>Frontiers in Microbiology</em>, vol. 17, 2026, article 1865548. Frontiers Media SA, 5 June 2026, doi:10.3389/fmicb.2026.1865548. <a href="https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1865548/full">https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1865548/full</a></p><p>Barron, Madeline. “Phage Therapy: Past, Present and Future.” <em>American Society for Microbiology</em>, 24 Feb. 2026. <a href="https://asm.org/articles/2022/august/phage-therapy-past,-present-and-future">https://asm.org/articles/2022/august/phage-therapy-past,-present-and-future</a></p><p>Iftikhar, Noreen. “Phage Therapy: How It Works, Pros and Cons, Availability, and More.” <em>Healthline</em>, 14 Jan. 2019. <a href="https://www.healthline.com/health/phage-therapy">https://www.healthline.com/health/phage-therapy</a></p><p>Khan Academy. “Bacteriophages.” <em>Khan Academy</em>. <a href="https://www.khanacademy.org/science/biology/biology-of-viruses/a/bacteriophages">https://www.khanacademy.org/science/biology/biology-of-viruses/a/bacteriophages</a></p><p>Lin, Derek M., Britt Koskella, and Henry C. Lin. “Phage Therapy: An Alternative to Antibiotics in the Age of Multi-Drug Resistance.” <em>World Journal of Gastrointestinal Pharmacology and Therapeutics</em>, vol. 8, no. 3, 2017, pp. 162–173. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5547374/">https://pmc.ncbi.nlm.nih.gov/articles/PMC5547374/</a></p><p>McMaster University. “Researchers Discover Why Some Bacteria-Killing Viruses Are More Effective Than Others.” <em>McMaster News</em>, 23 Sept. 2026. <a href="https://news.mcmaster.ca/why-some-bacteria-killing-viruses-are-more-effective-than-others/">https://news.mcmaster.ca/why-some-bacteria-killing-viruses-are-more-effective-than-others/</a></p><p>World Health Organization Regional Office for Europe. “Antimicrobial Resistance.” <em>World Health Organization</em>, 19 Sept. 2024. <a href="https://www.who.int/europe/news-room/fact-sheets/item/antimicrobial-resistance">https://www.who.int/europe/news-room/fact-sheets/item/antimicrobial-resistance</a></p><p>World Health Organization Regional Office for Europe. “Bacteriophages and Their Use in Combating Antimicrobial Resistance.” <em>World Health Organization</em>, 17 Feb. 2025. <a href="https://www.who.int/europe/news-room/fact-sheets/item/bacteriophages-and-their-use-in-combating-antimicrobial-resistance">https://www.who.int/europe/news-room/fact-sheets/item/bacteriophages-and-their-use-in-combating-antimicrobial-resistance</a></p><p>World Health Organization Regional Office for Europe. “Building Evidence for the Use of Bacteriophages against Antimicrobial Resistance.” <em>World Health Organization</em>, 25 June 2024. <a href="https://www.who.int/europe/news-room/25-06-2024-building-evidence-for-the-use-of-bacteriophages-against-antimicrobial-resistance">https://www.who.int/europe/news-room/25-06-2024-building-evidence-for-the-use-of-bacteriophages-against-antimicrobial-resistance</a></p><p>World Health Organization Regional Office for Europe. <em>Building the Evidence for the Use of Bacteriophage Therapy</em>. World Health Organization, 26 May 2025. <a href="https://www.who.int/europe/publications/i/item/WHO-EURO-2025-11441-51213-78039">https://www.who.int/europe/publications/i/item/WHO-EURO-2025-11441-51213-78039</a></p><p>World Health Organization Regional Office for Europe. “Webinar — Towards Building the Evidence for Broader Use of Bacteriophages from an AMR One Health Perspective.” <em>World Health Organization</em>, 18 Apr. 2024. <a href="https://www.who.int/europe/news-room/events/item/2024/04/18/default-calendar/webinar---towards-building-the-evidence-for-broader-use-of-bacteriophages-from-an-amr-one-health-perspective">https://www.who.int/europe/news-room/events/item/2024/04/18/default-calendar/webinar---towards-building-the-evidence-for-broader-use-of-bacteriophages-from-an-amr-one-health-perspective</a></p><p>“Phage Treatment of Multidrug-Resistant Bacterial Infections in Humans, Animals, and Plants: The Current Status and Future Prospects.” <em>International Microbiology</em>, 2025, article 100168. Elsevier. <a href="https://www.sciencedirect.com/science/article/pii/S2772431X25000073">https://www.sciencedirect.com/science/article/pii/S2772431X25000073</a></p><p>Lipman, Natasha. “‘My Husband Squeezed My Hand to Say He Wanted to Live, Then I Found a Way to Save Him.’” <em>BBC News</em>, 4 Nov. 2019, <a href="https://www.bbc.com/news/stories-50221375">https://www.bbc.com/news/stories-50221375</a>.</p><p><strong>About the Author</strong></p><p>Hi, my name is Aditi! I am a high school student passionate about Science. I always had a passion for science since I was a little girl; learning about new emerging technology’s in science is one of my favourite things to research! You can reach out to me through my email adititalwar777@gmail.com and my <a href="https://www.linkedin.com/in/aditi-t-5bb69142a/">LinkedIn</a>!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=36488155c724" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>